The estimated Net Worth of Stephen T Wills is at least $2.37 Миллион dollars as of 1 August 2024. Mr. Wills owns over 4,999 units of Palatin Technologies stock worth over $336,702 and over the last 22 years he sold PTN stock worth over $20,843. In addition, he makes $2,007,760 as Chief Financial Officer, Chief Operating Officer, Executive Vice President, Treasurer и Secretary at Palatin Technologies.
stephen has made over 26 trades of the Palatin Technologies stock since 2003, according to the Form 4 filled with the SEC. Most recently he sold 4,999 units of PTN stock worth $8,298 on 1 August 2024.
The largest trade he's ever made was exercising 300,000 units of Palatin Technologies stock on 26 March 2010 worth over $429,000. On average, stephen trades about 25,591 units every 111 days since 2002. As of 1 August 2024 he still owns at least 235,456 units of Palatin Technologies stock.
You can see the complete history of Mr. Wills stock trades at the bottom of the page.
stephen T. Wills CPA serves as Chief Financial Officer, Chief Operating Officer, Executive Vice President, Treasurer, Secretary of the Company. Mr. Wills serves on the boards of directors of MediWound Ltd. (Nasdaq: MDWD), a biopharmaceutical company focused on treatment in the fields of severe burns, chronic and other hard to heal wounds, since April 2017, and as Chairman since January 2018, of Gamida Cell Ltd. (Nasdaq: GMDA), a leading cellular and immune therapeutics company, since March 2019 (audit and finance committee member), and of Amryt Pharma, a biopharmaceutical company focused on developing and delivering treatments to help improve the lives of patients with rare and orphan diseases, since September 2019 (chairman of audit committee and member of the finance committee). Mr. Wills also serves on the board of trustees and executive committee of The Hun School of Princeton, a college preparatory day and boarding school, since 2013, and as its Chairman since June 2018. Mr. Wills served on the board of directors of Caliper Corporation, a psychological assessment and talent development company, since March 2016, and as Chairman from December 2016 to December 2019, when Caliper was acquired by PSI. Mr. Wills served as Executive Chairman and Interim Principal Executive Officer of Derma Sciences, Inc., a provider of advanced wound care products, from December 2015 to February 2017, when Derma Sciences was acquired by Integra Lifesciences (Nasdaq: IART). Previously, Mr. Wills served on the board of directors of Derma Sciences as the lead director and chairman of the audit committee from June 2000 to December 2015. Mr. Wills served as the Chief Financial Officer of Derma Sciences from 1997 to 2000. Mr. Wills served as the President and Chief Operating Officer of Wills, Owens & Baker, P.C., a public accounting firm, from 1991 to 2000. Mr. Wills, a certified public accountant, earned his Bachelor of Science in accounting from West Chester University, and a Master of Science in taxation from Temple University.
As the Chief Financial Officer, Chief Operating Officer, Executive Vice President, Treasurer и Secretary of Palatin Technologies, the total compensation of stephen Wills at Palatin Technologies is $2,007,760. There are 1 executives at Palatin Technologies getting paid more, with Carl Spana having the highest compensation of $2,274,410.
stephen Wills is 62, he's been the Chief Financial Officer, Chief Operating Officer, Executive Vice President, Treasurer и Secretary of Palatin Technologies since 2011. There are 7 older and 4 younger executives at Palatin Technologies. The oldest executive at Palatin Technologies Inc. is Robert deVeer, 74, who is the Independent Director.
Stephen's mailing address filed with the SEC is PALATIN TECHNOLOGIES, INC., 4B CEDAR BROOK DRIVE, CRANBURY, NJ, 08512.
Over the last 22 years, insiders at Palatin Technologies have traded over $3,929,269 worth of Palatin Technologies stock and bought 390,692 units worth $374,235 . The most active insiders traders include Austin W & Greenhouse David..., Partners L P/Ilbiotechnolog... и Carl Spana. On average, Palatin Technologies executives and independent directors trade stock every 76 days with the average trade being worth of $128,497. The most recent stock trade was executed by Stephen T Wills on 1 August 2024, trading 4,999 units of PTN stock currently worth $8,298.
palatin technologies, inc., a specialized biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the united states. the company's lead product is vyleesi, a melanocortin receptor agonist for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder. it is also developing oral pl8177, a selective melanocortin receptor (mcr) 1 agonist peptide that has completed phase i clinical trial for the treatment of inflammatory bowel diseases; and systemic pl8177, which has completed phase i clinical trial for treating non-infectious uveitis and covid-19. in addition, the company engages in the development of pl9643, a peptide melanocortin agonist active at multiple mcrs, including mc1r and mc5r for anti-inflammatory ocular indications, such as dry eye disease; and melanocortin peptides for diabetic retinopathy. further, it is developing pl3994, a natriuretic peptide receptor (npr)-a agonist and sy
Palatin Technologies executives and other stock owners filed with the SEC include: